The Stamets Stack

The Stamets Stack is a microdosing protocol proposed by the mycologist Paul Stamets that combines three things: a small amount of psilocybin mushroom, the functional mushroom Lion's Mane, and niacin (vitamin B3). The idea behind it is that the three act on complementary pathways, with psilocybin engaging the serotonin system, Lion's Mane supporting nerve growth, and niacin distributing both into peripheral tissue. It has attracted considerable interest despite limited controlled research on the combination itself, and none that tests the three-part stack against its parts.

Psylopedia does not publish doses or protocols. What follows describes what the stack is, what is claimed for it, and where the evidence and the risks sit.

The substances

Psilocybin mushrooms provide the primary active component. At microdose levels, the intent is subtle serotonergic engagement without perceptual disruption: no visual change, no loosening of the sense of self, nothing that would make an ordinary Tuesday feel unusual. Whether that threshold is reliably achievable is itself contested, since individual sensitivity and mushroom potency both vary widely, and the same amount that registers as nothing for one person may register as something for another.

Lion's Mane (Hericium erinaceus) is a functional mushroom, edible, white, cascading in soft spines like a frozen waterfall, and it has been studied for its potential to stimulate nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). Most of that work is in cell cultures and rodents. Whether oral supplementation meaningfully raises NGF in a human brain remains debated, and the compounds implicated (hericenones and erinacines) face the ordinary problem of crossing from gut to blood to brain in a useful quantity.

Niacin (vitamin B3) is included as a vasodilator. The proposed rationale is that the niacin flush, the hot prickling redness that spreads across the face and chest, drives the other compounds into peripheral tissue where nerve regeneration is thought to be needed. This mechanism is not established in peer-reviewed research. It is a hypothesis, offered as one, and it has been repeated often enough that it now often gets stated as fact.

Why people reach for it

The stack is usually taken up for the same reasons any microdosing practice is: focus, mood, creative flow, a sense of the day having a little more grip to it. Stamets has additionally framed it in terms of neurogenesis, the growth of new neural tissue, which gives the practice a longer horizon than a single morning. That framing is part of the appeal. It suggests the practice is building something rather than borrowing from tomorrow.

The honest position is that this is a promising hypothesis with a thin evidence base underneath it. The largest microdosing studies to date, including placebo-controlled and self-blinding designs, have generally found that expectancy accounts for a substantial share of reported benefit. That does not mean nothing is happening. It means we cannot yet say confidently what.

What tends to happen

Subjective reports vary widely. Some people find the stack supportive for focus, mood, and creative work, and describe the effect as a slight widening of patience rather than a stimulant lift. Others notice little beyond what they might expect from psilocybin alone. A smaller group report the opposite of what they hoped: mild anxiety, a scattered quality of attention, or a low-grade physical restlessness.

The Lion's Mane and niacin components, if they contribute at all, are thought to work cumulatively over weeks rather than acutely within a session. Nothing about this combination is designed to be felt in the moment, which makes it unusually hard to evaluate from the inside. A practice whose effects are subtle, delayed, and expectation-sensitive is a practice where a person can convince themselves of almost anything.

The risk picture

Serotonergic interactions come first. Psilocybin should not be combined with SSRIs, SNRIs, MAOIs, tramadol, lithium, or other serotonergic medications without medical guidance. Lithium in particular has been associated with seizures in combination with psychedelics. If you take any of these, this is not a "start low and see" situation. See the MAOI and interaction checker.

Niacin flush is unpleasant and, at higher intakes, not benign. The flush itself is harmless but can be intense: burning skin, redness, sometimes a headache. Sustained high-dose niacin has been associated with liver strain, particularly in slow-release forms.

Psilocybin remains a controlled substance in most jurisdictions, and legal exposure does not scale down with the amount taken. A small quantity is still possession.

Tolerance and drift. Psilocybin tolerance builds quickly, which is why cycled schedules exist at all. The subtler risk is not pharmacological but behavioral: a daily practice that quietly becomes load-bearing, taken not for what it adds but because stopping feels like losing ground.

Who it tends not to suit

People with a personal or family history of psychosis, bipolar disorder, or schizophrenia are generally advised away from psilocybin in any amount, including microdoses. People in acute mental health crisis are poorly served by a practice that takes weeks to evaluate. People on any serotonergic medication need a clinician, not a protocol.

Context and integration

Microdosing is often framed as the version of this work that does not need a container, since nothing dramatic happens and life continues around it. That framing is worth resisting a little. The practices that seem to hold up over time tend to have some structure: a reason for starting, a way of noticing, an agreed point at which to stop and look back at whether anything changed. A brief written note on dosing days, made before the day unfolds rather than after, is one of the few tools that can distinguish an effect from an expectation.

There is no single right way to hold this. But a practice with no way of being wrong is not really a practice.

For educational purposes only. Not medical advice.